Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $700000.0.

  • SAB Biotherapeutics' Depreciation & Amortization (CF) fell 2222.22% to $700000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 3707.55%. This contributed to the annual value of $4.7 million for FY2024, which is 2718.3% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Depreciation & Amortization (CF) stood at $700000.0, which was down 2222.22% from $800000.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Depreciation & Amortization (CF) registered a high of $2.0 million during Q1 2024, and its lowest value of $235959.0 during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $811663.9, with a median of $800000.0 in 2025.
  • In the last 5 years, SAB Biotherapeutics' Depreciation & Amortization (CF) skyrocketed by 18969.72% in 2022 and then crashed by 6000.0% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Depreciation & Amortization (CF) (Quarter) stood at $619984.0 in 2021, then skyrocketed by 49.9% to $929379.0 in 2022, then rose by 4.3% to $969340.0 in 2023, then dropped by 21.18% to $764007.0 in 2024, then dropped by 8.38% to $700000.0 in 2025.
  • Its last three reported values are $700000.0 in Q3 2025, $800000.0 for Q2 2025, and $800000.0 during Q1 2025.